<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03527368</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00155640</org_study_id>
    <secondary_id>17SFRN33590069</secondary_id>
    <nct_id>NCT03527368</nct_id>
  </id_info>
  <brief_title>The Time-Restricted Intake of Meals Study</brief_title>
  <acronym>TRIM</acronym>
  <official_title>The Time-Restricted Intake of Meals Study: A Randomized, Controlled Feeding Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      TRIM is a randomized, controlled feeding study to evaluate if eating earlier in the day vs.&#xD;
      later in the day impacts weight and glucose homeostasis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 24, 2018</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 23, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight Change</measure>
    <time_frame>12 weeks</time_frame>
    <description>Weight change will be measured in kg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting glucose</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in fasting glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA-IR</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in HOMA-IR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC glucose</measure>
    <time_frame>12 weeks</time_frame>
    <description>Area-under-the-curve for glucose on OGTT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycated albumin</measure>
    <time_frame>12 weeks</time_frame>
    <description>Glycated albumin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>PreDiabetes</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Time-restricted feeding</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual feeding pattern</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Comparison</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Time-restricted feeding</intervention_name>
    <description>Participants consume food earlier in the day</description>
    <arm_group_label>Time-restricted feeding</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Usual feeding pattern</intervention_name>
    <description>Participants consume food later in the day</description>
    <arm_group_label>Usual feeding pattern</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Prediabetes defined by HbA1c 5.7-6.4%, or type 2 diabetes with HbA1c 6.5-6.9%&#xD;
&#xD;
          -  Class I-III obesity (BMI 30-50 kg/m2)&#xD;
&#xD;
          -  If on medications for hypertension, stable regimen for at least past 6 months&#xD;
&#xD;
          -  Willingness to adjust timing of feeding&#xD;
&#xD;
          -  Willingness and ability to eat study diet and nothing else during run-in and&#xD;
             intervention&#xD;
&#xD;
          -  Willingness to complete measurement procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Moderate to severe obstructive sleep apnea&#xD;
&#xD;
          -  Shift work;&#xD;
&#xD;
          -  Other sleep/circadian disorders: e.g., circadian phase delay or phase advance;&#xD;
             restless legs syndrome, insomnia, narcolepsy, habitual sleep &lt;6 hours/night&#xD;
&#xD;
          -  Routinely ate within compressed time window in the past year (e.g., routinely eats all&#xD;
             food within an 10-hour or narrower window, follows an intermittent fasting protocol)&#xD;
&#xD;
          -  Renal dysfunction (estimated Glomerular Filtration Rate (GFR) &lt;30 using the simplified&#xD;
             Chronic Kidney Disease (CKD) Epidemiology Collaboration (EPI) equation 34)&#xD;
&#xD;
          -  Use of glucose-lowering medications, weight loss medications, medications for sleep&#xD;
             disorders (sedative/hypnotic drugs, stimulants), lithium, systemic corticosteroids,&#xD;
             diuretics, blood thinners requiring regular monitoring (e.g. warfarin), anti-psychotic&#xD;
             drugs and antiretroviral therapy&#xD;
&#xD;
          -  Body weight &gt;400 pounds (limitation of facility scales)&#xD;
&#xD;
          -  &gt;1 drink per day of alcohol&#xD;
&#xD;
          -  Active substance use disorder or significant psychiatric/psychologic disorder that&#xD;
             would interfere with participation&#xD;
&#xD;
          -  Significant food allergies, preferences, intolerances, or dietary supplements that&#xD;
             would interfere with diet adherence&#xD;
&#xD;
          -  Weight loss or gain of â‰¥5% during past 6 months&#xD;
&#xD;
          -  Pregnant, planning to become pregnant, or breastfeeding&#xD;
&#xD;
          -  Planning to start a weight loss program&#xD;
&#xD;
          -  Planning to leave the area prior to end of study&#xD;
&#xD;
          -  Current participation in another clinical trial&#xD;
&#xD;
          -  Cancer diagnosis requiring active treatment in past two years or planned treatment&#xD;
             (with exception of localized non-melanoma skin cancer)&#xD;
&#xD;
          -  Active inflammatory bowel disease, malabsorption, or history of major gastrointestinal&#xD;
             surgery involving bowel resection&#xD;
&#xD;
          -  Myocardial infarction or stroke in past 6 months&#xD;
&#xD;
          -  Prior bariatric surgery&#xD;
&#xD;
          -  Any serious illness that would interfere with participation&#xD;
&#xD;
          -  Other conditions or situations at the discretion of the PI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nisa Maruthur, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins ProHealth</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 4, 2018</study_first_submitted>
  <study_first_submitted_qc>May 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2018</study_first_posted>
  <last_update_submitted>May 13, 2021</last_update_submitted>
  <last_update_submitted_qc>May 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

